Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Appointed director
Inv. presentation
Quarterly results
Appointed COO
|
|
TIANYIN PHARMACEUTICAL CO., INC. (TPI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/18/2016 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 05/05/2016 |
8-K
| Quarterly results |
| 04/07/2016 |
8-K
| Form 8-K - Current report |
| 03/02/2016 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 02/17/2016 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/11/2016 |
8-K/A
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"TPI Received Acceptance Letter From NYSE MKT Regarding its Plan of Compliance with Continued Listing Requirements Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , received a plan acceptance letter on January 5, 2016 from the NYSE MKT LLC indicating that the Exchange accepted the Company’ s compliance plan, submitted on October 19, 2015 and supplemented on December 4, 2015, regarding the Company’ s non-compliance of certain of the Exchange’ s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide. The Company was notified by the Exchange previously of its noncompliance of the continued listing s..." |
|
| 12/23/2015 |
8-K/A
| Other Events |
| 12/02/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , received notice on November 25, 2015 from the NYSE MKT LLC indicating that the Company is below certain of the Exchange’ s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2015 , in addition to the delay in filing of its Annual Report on Form 10-K for the year ended June 30, 2015 . Under NYSE MKT rules, until the Company files the Form 10-Q and Form 10-K, its c..." |
|
| 10/19/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"TPI Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , received notice on October 16, 2015 from the NYSE MKT LLC indicating that the Company is below certain of the Exchange’ s continued listing standards, as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing of its Annual Report on Form 10-K for the year ended June 30, 2015 . Under NYSE MKT rules, until the Company files the Form 10-K, its common stock will remain listed on the NYSE MKT under the symbol “TPI,” but will be assigned an “.LF” indicator to signify late fi..." |
|
| 10/16/2015 |
8-K
| Other Events |
| 09/22/2015 |
8-K
| Other Events |
| 08/20/2015 |
10-Q/A
| Quarterly Report for the period ended December 31, 2014 [amend] |
| 08/11/2015 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review |
| 08/11/2015 |
10-Q
| Quarterly Report for the period ended March 31, 2015 |
| 07/17/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 07/14/2015 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets |
| 06/25/2015 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/22/2015 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 05/26/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to... |
| 03/31/2015 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/13/2015 |
10-Q
| Quarterly Report for the period ended December 31, 2014 |
| 02/26/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 02/06/2015 |
8-K/A
| Other Events, Financial Statements and Exhibits |
| 01/28/2015 |
8-K
| Appointed a new director |
| 01/16/2015 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"TPI to Form Strategic Alliance with Buchang Pharma CHENGDU, China, Jan. 14, 2015 /PRNewswire/ -- Tianyin Pharmaceutical Co., Inc. , a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients today announced that TPI and Buchang Pharmaceutical Co., Ltd. plan to establish Tianyin-Buchang Strategic Alliance to synergize and accelerate the growth of the Company, boosting TPI's mTCM franchise focusing on its cardiovascular revenue driver Gingko Mihuan . 1. The Alliance platform will be established based upon TPI's newly completed and GMP-certified Qionglai Tianyin Facility with the latest technologies and expanded production capacities in mTCM pre-extraction, purification and formulati..." |
|
| 01/06/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/31/2014 |
10-Q
| Quarterly Report for the period ended September 30, 2014 |
| 12/09/2014 |
10-K
| Annual Report for the period ended June 30, 2014 |
| 10/27/2014 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/21/2014 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...|
Docs:
|
"Tianyin Pharmaceutical Received Notices of Non-Compliance from NYSE MKT Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , today reported that, on October 15, 2014, it received a notice from the NYSE MKT Staff indicating that the Company is below certain of the continued listing standards of the NYSE MKT as set forth in Sections 134 and 1101 of the NYSE MKT Company Guide, due to the delay in filing its Annual Report on Form 10-K for fiscal year ended June 30, 2014 beyond the extended filing due date of October 14, 2014. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will rem..." |
|
| 10/16/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/15/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 CHENGDU, China, Oct. 15, 2014 /PRNewswire/ -- Tianyin Pharmaceutical Inc. , a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine , branded generics and active pharmaceutical ingredients , today reported that it has delayed the filing of its Annual Report on Form 10-K for the year ended June 30, 2014 beyond the extended filing due date of October 14, 2014. As TPI indicated in its Current Reports on Form 8-K filed on October 8, 2013 and November 4, 2013, its Audit Committee and the Board of Directors both unanimously approved the termination of the Company's independent auditor, Patrizio and Zhao LLC..." |
|
| 07/08/2014 |
8-K/A
| Other Events |
| 06/23/2014 |
8-K/A
| Other Events |
|
|
|